BMO Capital raised the firm’s price target on Terns Pharmaceuticals (TERN) to $30 from $22 and keeps an Outperform rating on the shares. The opportunity for TERN-701 in CML remains underappreciated as Phase 1 CARDINAL abstract data has been clearly differentiated against existing therapies, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TERN:
- Terns Pharmaceuticals: Promising Clinical Results and Strong Financial Position Justify Buy Rating
- Terns Pharmaceuticals price target raised to $33 from $32 at Mizuho
- Terns Pharmaceuticals Reports Q3 2025 Results and Updates
- Terns Pharmaceuticals price target raised to $28 from $27 at Barclays
- Promising Outlook for Terns Pharmaceuticals: Buy Rating Backed by Strong Financials and Potential Breakthrough in Leukemia Treatment